Pharmacokinetics and Pharmacodynamics of a Chimeric/Humanized Anti-CD3 Monoclonal Antibody, Otelixizumab (TRX4), in Subjects With Psoriasis and With Type 1 Diabetes Mellitus - Publication - Bridge of Knowledge

Search

Pharmacokinetics and Pharmacodynamics of a Chimeric/Humanized Anti-CD3 Monoclonal Antibody, Otelixizumab (TRX4), in Subjects With Psoriasis and With Type 1 Diabetes Mellitus

Abstract

Citations

  • 3 2

    CrossRef

  • 0

    Web of Science

  • 3 8

    Scopus

Authors (4)

  • Photo of prof. dr hab. Paweł Wiczling

    Paweł Wiczling prof. dr hab.

  • Photo of  Michael Rosenzweig

    Michael Rosenzweig

  • Photo of  Louis Vaickus

    Louis Vaickus

  • Photo of  William Jusko

    William Jusko

Cite as

Full text

full text is not available in portal

Details

Category:
Magazine publication
Type:
Magazine publication
Published in:
JOURNAL OF CLINICAL PHARMACOLOGY no. 50, edition 5, pages 494 - 506,
ISSN: 0091-2700
ISSN:
00912700
Publication year:
2010
DOI:
Digital Object Identifier (open in new tab) 10.1177/0091270009349376
Verified by:
No verification

seen 36 times

Meta Tags